Bioventus Inc. financial data

Symbol
BVS on Nasdaq
Location
Durham, NC
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 04 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 148% % 2.4%
Quick Ratio 52% % 12%
Debt-to-equity 329% % -10%
Return On Equity 5.2% %
Return On Assets 1.4% %
Operating Margin 8% %

Shares

Label TTM Value / Value Unit Change %
Entity Public Float $176,600,000 USD 134%
Weighted Average Number of Shares Outstanding, Basic 66,924,682 shares 2.6%
Weighted Average Number of Shares Outstanding, Diluted 68,837,797 shares 5.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $563,829,000 USD 1.6%
Research and Development Expense $12,065,000 USD -13%
Operating Income (Loss) $45,408,000 USD 209%
Nonoperating Income (Expense) $30,679,000 USD 21%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $14,729,000 USD
Income Tax Expense (Benefit) $2,160,000 USD 13%
Net Income (Loss) Attributable to Parent $10,172,000 USD
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $42,164,000 USD -2.1%
Accounts Receivable, after Allowance for Credit Loss, Current $130,404,000 USD 7%
Inventory, Net $96,273,000 USD 6.9%
Assets, Current $280,901,000 USD -6%
Deferred Income Tax Assets, Net $4,745,000 USD -36%
Operating Lease, Right-of-Use Asset $5,830,000 USD -40%
Intangible Assets, Net (Excluding Goodwill) $377,398,000 USD -9%
Goodwill $7,462,000 USD 0%
Assets $701,593,000 USD -8.8%
Accounts Payable, Current $26,649,000 USD 58%
Accrued Liabilities, Current $119,446,000 USD -7.2%
Contract with Customer, Liability, Current $1,679,000 USD -28%
Liabilities, Current $161,752,000 USD -24%
Deferred Income Tax Liabilities, Net $786,000 USD
Operating Lease, Liability, Noncurrent $5,214,000 USD -33%
Other Liabilities, Noncurrent $20,466,000 USD -22%
Liabilities $494,338,000 USD -15%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,837,000 USD -513%
Retained Earnings (Accumulated Deficit) $349,684,000 USD 1.5%
Stockholders' Equity Attributable to Parent $166,096,000 USD 12%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $207,255,000 USD 11%
Liabilities and Equity $701,593,000 USD -8.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $19,331,000 USD -222%
Net Cash Provided by (Used in) Financing Activities $947,000 USD
Net Cash Provided by (Used in) Investing Activities $826,000 USD 17%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $18,780,000 USD -59%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $42,164,000 USD -2.1%
Deferred Tax Assets, Valuation Allowance $51,875,000 USD 13%
Deferred Tax Assets, Gross $56,620,000 USD 21%
Operating Lease, Liability $8,740,000 USD -20%
Payments to Acquire Property, Plant, and Equipment $826,000 USD 184%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $7,890,000 USD
Lessee, Operating Lease, Liability, to be Paid $10,852,000 USD -32%
Operating Lease, Liability, Current $3,526,000 USD 13%
Lessee, Operating Lease, Liability, to be Paid, Year Two $3,329,000 USD -18%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,487,000 USD -24%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $810,000 USD -41%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,659,000 USD -18%
Deferred Tax Assets, Operating Loss Carryforwards $9,224,000 USD -15%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $3,735,000 USD -21%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,367,000 USD -48%
Operating Lease, Payments $892,000 USD -24%
Additional Paid in Capital $517,534,000 USD 2.9%
Depreciation, Depletion and Amortization $11,865,000 USD 0.68%
Deferred Tax Assets, Net of Valuation Allowance $4,745,000 USD 465%
Share-based Payment Arrangement, Expense $7,920,000 USD 27%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%